Analysts Set Expectations for Zomedica FY2024 Earnings

Zomedica Corp. (NYSEAMERICAN:ZOM) – Equities research analysts at Noble Financial issued their FY2024 earnings per share estimates for shares of Zomedica in a research note issued on Monday, November 11th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings of ($0.05) per share for the year. Noble Financial has a “Strong-Buy” rating on the stock. The consensus estimate for Zomedica’s current full-year earnings is ($0.05) per share. Noble Financial also issued estimates for Zomedica’s Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.03) EPS.

Zomedica Price Performance

Shares of Zomedica stock opened at $0.14 on Thursday. Zomedica has a 52 week low of $0.12 and a 52 week high of $0.23. The company has a market capitalization of $132.29 million, a PE ratio of -2.29 and a beta of 1.06.

Institutional Trading of Zomedica

A number of institutional investors and hedge funds have recently modified their holdings of ZOM. Virtu Financial LLC boosted its stake in Zomedica by 1,585.0% in the first quarter. Virtu Financial LLC now owns 168,773 shares of the company’s stock valued at $25,000 after acquiring an additional 158,757 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Zomedica in the 3rd quarter worth approximately $25,000. Finally, Price T Rowe Associates Inc. MD lifted its stake in Zomedica by 41.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 948,300 shares of the company’s stock valued at $139,000 after purchasing an additional 276,100 shares during the last quarter. 8.95% of the stock is owned by hedge funds and other institutional investors.

Zomedica Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.